Three New FDA approved ADCs


FDA approved three new antibody-drug conjugates to treat cancer by linking up to the proteins on tumor cells’ surfaces. The chemical and biological processes break up the linkers once the ADCs interact with the tumor cells, and then the payloads are released killing the tumor cells. Many companies still see them potentially as “guided missiles”. The challenge is to kill the tumor cells without affecting the non tumor cells. Daiichi Sankyo and AstraZeneca’s Enhertu were able to carry about eight DXd moieties compared to most ADCs that carry two to four payload molecules.

 

Source: https://cen.acs.org/biological-chemistry/cancer/new-generation-antibody-drug-conjugates/98/i14

#research #PEGlinkers #PEGylation #PEGvendor #PROTAC #dyelabeling #bioconjugation #chemistry #PEGsupply #PEGreagent #drugdiscovery #drugdelivery #amino #antibodies #ADCs #conjugates #cancer #FDA